Sonnet Historical Financial Ratios
| SONN Stock | USD 2.89 0.03 1.03% |
Sonnet Biotherapeutics is promptly reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 34 K, Invested Capital of 0.0, Average Payables of 3.6 M or Stock Based Compensation To Revenue of 1.41 will help investors to properly organize and evaluate Sonnet Biotherapeutics financial condition quickly.
Sonnet |
About Sonnet Financial Ratios Analysis
Sonnet BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Sonnet Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Sonnet financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Sonnet Biotherapeutics history.
Sonnet Biotherapeutics Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Ev To Free Cash Flow
A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.Most ratios from Sonnet Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Sonnet Biotherapeutics' Graham Number is very stable compared to the past year. As of the 22nd of November 2024, Shareholders Equity Per Share is likely to grow to about 33 K, while Price To Sales Ratio is likely to drop 1.12.
| 2021 | 2024 (projected) | Interest Debt Per Share | 0.003788 | 29.4K | Revenue Per Share | 1.77 | 91.8K |
Sonnet Biotherapeutics fundamentals Correlations
Click cells to compare fundamentals
Sonnet Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sonnet Biotherapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 1.28 | 1.18 | 245.82 | 145.84 | 160.99 | 1.12 | |
| Ptb Ratio | 4.88 | 64.07 | 5.34 | (20.1) | (105.3) | 5.12 | |
| Book Value Per Share | 18.8K | 98.74 | 279.3 | (12.86) | (0.22) | 34.0K | |
| Free Cash Flow Yield | (0.0775) | (0.0811) | (0.19) | (0.56) | (0.92) | (0.0813) | |
| Operating Cash Flow Per Share | (2.5K) | (510.54) | (282.97) | (140.22) | (20.56) | (2.7K) | |
| Capex To Depreciation | 0.94 | 1.31 | 0.0381 | 9.61 | 5.85 | 1.85 | |
| Pb Ratio | 4.88 | 64.07 | 5.34 | (20.1) | (105.3) | 5.12 | |
| Free Cash Flow Per Share | (6.4K) | (513.03) | (283.01) | (144.76) | (20.98) | (6.7K) | |
| Roic | (0.16) | (9.8) | (1.13) | 11.71 | 83.16 | (0.15) | |
| Net Income Per Share | (15.6K) | (1.0K) | (313.76) | (150.79) | (18.14) | (16.4K) | |
| Payables Turnover | 12.57 | 0.0283 | 4.4 | 0.0196 | 5.37 | 6.53 | |
| Sales General And Administrative To Revenue | 0.11 | 0.0118 | 18.48 | 24.5 | 48.21 | 0.0112 | |
| Capex To Revenue | 0.0392 | 0.0553 | 0.007491 | 2.56 | 3.0 | 0.0525 | |
| Cash Per Share | 1.2K | 240.31 | 346.58 | 15.46 | 2.19 | 1.6K | |
| Pocfratio | (32.67) | (12.39) | (5.27) | (1.84) | (1.11) | (34.31) | |
| Capex To Operating Cash Flow | (1.53) | (0.004879) | (1.61E-4) | (0.0324) | (0.0208) | (1.45) | |
| Pfcf Ratio | (12.91) | (12.33) | (5.27) | (1.79) | (1.09) | (13.56) | |
| Days Payables Outstanding | 29.03 | 12.9K | 82.97 | 18.6K | 68.03 | 27.58 | |
| Income Quality | 0.16 | 0.64 | 0.9 | 0.93 | 1.13 | 0.15 | |
| Roe | (0.92) | (10.29) | (1.12) | 11.73 | 83.34 | (0.88) | |
| Ev To Operating Cash Flow | (41.52) | (11.94) | (4.05) | (1.74) | (1.02) | (43.59) | |
| Pe Ratio | (5.29) | (6.23) | (4.75) | (1.71) | (1.26) | (5.55) | |
| Return On Tangible Assets | (1.63) | (3.89) | (0.86) | (5.11) | (3.47) | (1.72) | |
| Ev To Free Cash Flow | (16.4) | (11.89) | (4.05) | (1.69) | (1.0) | (17.22) | |
| Earnings Yield | (0.19) | (0.16) | (0.21) | (0.58) | (0.79) | (0.2) | |
| Net Debt To E B I T D A | (2.65) | 0.29 | 1.1 | 0.0946 | 0.11 | (2.52) | |
| Current Ratio | 0.1 | 1.62 | 4.3 | 0.66 | 0.86 | 0.098 | |
| Tangible Book Value Per Share | (39.4K) | 98.74 | 279.3 | (12.86) | (0.22) | (37.5K) | |
| Graham Number | 77.0K | 1.5K | 1.4K | 208.85 | 9.43 | 124.6K | |
| Shareholders Equity Per Share | 16.9K | 98.74 | 279.3 | (12.86) | (0.22) | 33.0K |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.